Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

Molecular Neurodegeneration

Lili Zhang¹  Eric M Parker²  J Fred Hess²  Lynn Hyde²  Xiaohai Wang⁵  Giuseppe Terracina²  Julie Lee²  Jerry Melchor⁴  Xuesong Ouyang⁶  Sherry X Lu²  Lixin Song³ 

[1] Current address: Department of Neuroscience, Novartis Institute for Biomedical Research, Cambridge, MA, USA;Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ, USA;Current address: BioDuro, a PPD Company, Beijing, China;Current address: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA;In Vivo Pharmacology, Merck Research Laboratories, West Point, PA, USA;Current address: Medical Oncology Department, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

关键词: CSF tau;    rTg4510;    Tau acetylation;    Tau phosphorylation;    Tau aggregation;    Tau;    Neurodegeneration;    Alzheimer’s disease;   

Others  :  1160774
DOI  :  10.1186/s13024-015-0011-1

 received in 2014-04-05, accepted in 2015-03-02,  发布年份 2015

【 摘 要 】

Background

Microtubule associated protein tau is the major component of the neurofibrillary tangles (NFTs) found in the brains of patients with Alzheimer’s disease and several other neurodegenerative diseases. Tau mutations are associated with frontotemperal dementia with parkinsonism on chromosome 17 (FTDP-17).rTg4510 mice overexpress human tau carrying the P301L FTDP-17 mutation and develop robust NFT-like pathology at 4–5 months of age. The current study is aimed at characterizing the rTg4510 mice to better understand the genesis of tau pathology and to better enable the use of this model in drug discovery efforts targeting tau pathology.

Results

Using a panel of immunoassays, we analyzed the age-dependent formation of pathological tau in rTg4510 mice and our data revealed a steady age-dependent accumulation of pathological tau in the insoluble fraction of brain homogenates. The pathological tau was associated with multiple post-translational modifications including aggregation, phosphorylation at a wide variety of sites, acetylation, ubiquitination and nitration. The change of most tau species reached statistical significance at the age of 16 weeks. There was a strong correlation between the different post-translationally modified tau species in this heterogeneous pool of pathological tau. Total tau in the cerebrospinal fluid (CSF) displayed a multiphasic temporal profile distinct from the steady accumulation of pathological tau in the brain. Female rTg4510 mice displayed significantly more aggressive accumulation of pathological tau in the brain and elevation of total tau in CSF than their male littermates.

Conclusion

The immunoassays described here were used to generate the most comprehensive description of the changes in various tau species across the lifespan of the rTg4510 mouse model. The data indicate that development of tauopathy in rTg4510 mice involves the accumulation of a pool of pathological tau that carries multiple post-translational modifications, a process that can be detected well before the histological detection of NFTs. Therapeutic treatment targeting tau should therefore aim to reduce all tau species associated with the pathological tau pool rather than reduce specific post-translational modifications. There is still much to learn about CSF tau in physiological and pathological processes in order to use it as a translational biomarker in drug discovery.

【 授权许可】

   
2015 Song et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Mandelkow EM, Mandelkow E: Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012, 2:a006247.
• [2]Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Ann Rev Neurosci 2001, 24:1121-59.
• [3]Selkoe DJ: Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-66.
• [4]Martin L, Latypova X, Terro F: Post-translational modifications of tau protein: Implications for Alzheimer’s disease. Neurochem Int 2011, 58:458-71.
• [5]Avila J, Lucas JJ, Perez M, Hernandez F: Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004, 84:361-84.
• [6]Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131-44.
• [7]Goedert M, Jakes R: Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta 2005, 1739:240-50.
• [8]Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al.: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-5.
• [9]Götz J, Deters N, Doldissen A, Bokhari L, Ke Y, Wiesner A, et al.: A decade of tau transgenic animal models and beyond. Brain Pathol 2007, 17:91-103.
• [10]SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-81.
• [11]Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, et al.: Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005, 25:10637-47.
• [12]Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al.: Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 2007, 27:3650-64.
• [13]Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al.: The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011, 2:252.
• [14]Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al.: Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67:953-65.
• [15]Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ: Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 2006, 281:10825-38.
• [16]Reynolds MR, Reyes JF, Fu Y, Bigio EH, Guillozet-Bongaarts AL, Berry RW, et al.: Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer’s disease and other tauopathies. J Neurosci 2006, 26:10636-45.
• [17]Reyes JF, Fu Y, Vana L, Kanaan NM, Binder LI: Tyrosine nitration within the proline-rich region of Tau in Alzheimer’s disease. Acta Neuropathol 2012, 123:119-32.
• [18]Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, et al.: Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 2006, 168:1598-607.
• [19]Sahara N, DeTure M, Ren Y, Ebrahim AS, Kang D, Knight J, et al.: Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimer’s Dis 2013, 33:249-63.
• [20]Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, et al.: In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci 2011, 31:13110-7.
• [21]Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP: Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep 2013, 14:389-94.
• [22]Kim W, Lee S, Hall GF: Secretion of human tau fragments resembling CSF-tau in Alzheimer’s disease is modulated by the presence of the exon 2 insert. FEBS Lett 2010, 584:3085-8.
• [23]Gendreau KL, Hall GF: Tangles, toxicity, and tau secretion in AD - new approaches to a vexing problem. Front Neurol 2013, 4:160.
• [24]Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL, Yang L, et al.: Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimer’s Dis 2011, 24(Suppl 2):127-41.
• [25]Yue M, Hanna A, Wilson J, Roder H, Janus C: Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiol Aging 2011, 32:590-603.